# Platform Trial For Cryptococcal Meningitis

> **NCT06666322** · PHASE2,PHASE3 · RECRUITING · sponsor: **University of Minnesota** · enrollment: 2000 (estimated)

## Conditions studied

- Hiv
- Cryptococcal Meningitis

## Interventions

- **DRUG:** Standard of care
- **DRUG:** Oteseconazole - antifungal therapy 1
- **DRUG:** Sfu-AM2-19 Injection - antifungal therapy 2
- **DRUG:** Antifungal therapy 3
- **DRUG:** Antifungal therapy 4

## Key facts

- **NCT ID:** NCT06666322
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-28
- **Primary completion:** 2032-04-21
- **Final completion:** 2032-04-21
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06666322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06666322, "Platform Trial For Cryptococcal Meningitis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06666322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*